In summary, there appears to be a trend of increased expression of MMP-2, -7, -9 and TIMP-1 in the blood and increased expression of MMP-2, -7, -14, -15 and -26 tissue during malignant progression of prostate cancer, but more carefully designed perspective studies are needed to determine the clinical utility of these MMPs as biomarkers in prostate cancer. This evidence concerns the gene MMP2 and prostate cancer.